Search for a trial

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples in a first line setting from patients diagnosed with metastatic Colorectal Cancer (mCRC) to determine the KRAS G12C mutation status as part of the inclusion criteria into the Amgen Phase III clinical trial (Protocol No 20210081) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit.

To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen*s Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of…

Physical prehabilitation in patients with head and neck cancer scheduled for a laryngectomy; a feasibility study

The aim of this study is both a feasibility study to gain a comprehensive understanding of the feasibility, satisfaction and impact, and trends of the effects of a physical exercise and nutritional intervention in patients who will be treated by a…

MOVADECT

MAIN GOAL: We will integrate population-level registry (CBS) data and data from a survey on beliefs, values, and behavior to build a model to predict SARS-CoV-2 vaccination uptake on a population and local level. This model will take into account…